格隆汇2月2日丨迈得医疗(688310.SH)公布，截至2026年1月31日，本次公司通过集中竞价交易方式已累 计回购公司股份1,297,052股，占公司总股本的比例为0.7803%，回购成交的最高价为16.20元/股，最低 价为15.69元/股，支付的资金总额为人民币20,660,204.79元（不含印花税、交易佣金等交易费用）。 ...

格隆汇2月2日丨迈得医疗(688310.SH)公布，截至2026年1月31日，本次公司通过集中竞价交易方式已累 计回购公司股份1,297,052股，占公司总股本的比例为0.7803%，回购成交的最高价为16.20元/股，最低 价为15.69元/股，支付的资金总额为人民币20,660,204.79元（不含印花税、交易佣金等交易费用）。 ...

截至2026年1月30日收盘，迈得医疗(688310)报收于16.3元，上涨1.62%，换手率2.2%，成交量3.66万 手，成交额5921.43万元。 公司公告汇总 迈得医疗工业设备股份有限公司拟向控股子公司浙江迈得顺隐形眼镜有限公司提供总额不超过人民币1 亿元的财务资助，资助期限为自股东会审议通过之日起3年内，借款利率参照一年期LPR，利息按实际 借款占用天数计算。迈得顺可循环使用额度。公司实际控制人林军华、持股5%以上股东陈万顺为本次 资助提供连带责任保证。本次资助事项构成关联交易，不构成重大资产重组。董事会已提请股东会授权 管理层办理相关协议签署及款项支付等事宜。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月30日主力资金净流出114.8万元，占总成交额1.94%。 来自公司公告汇总：迈得医疗拟向控股子公司浙江迈得顺提供不超过1亿元财务资助，借款利率参 照一年期LPR。 当日关注点 交易信息汇总资金流向 1月30日主力资金净流出114.8万元，占总成交额1.94%；游资资金净流出279.94万元，占 ...

公司公告汇总 迈得医疗拟向控股子公司浙江迈得顺隐形眼镜有限公司提供总额不超过1亿元的财务资助，期限自股东 会审议通过之日起3年内，借款利率参照一年期LPR，利息按实际占用天数计算，额度可循环使用。公 司实控人林军华及持股5%以上股东陈万顺为本次资助提供连带责任保证。该事项构成关联交易，不构 成重大资产重组。董事会已提请股东会授权管理层办理相关协议签署及付款事宜。 截至2026年1月30日收盘，迈得医疗（688310）报收于16.3元，较上周的16.52元下跌1.33%。本周，迈 得医疗1月27日盘中最高价报18.0元。1月30日盘中最低价报15.87元。迈得医疗当前最新总市值27.09亿 元，在自动化设备板块市值排名73/78，在两市A股市值排名4838/5184。 本周关注点 业绩披露要点 迈得医疗发布业绩预告，预计2025年全年营业收入44,749.77万元左右，同比增长62.81%；归属于母公 司所有者的净利润为6,652.13万元左右，实现扭亏为盈；扣除非经常性损益后的净利润为5,463.95万元左 右。业绩增长主要得益于药械组合类智能装备收入显著提升。本期业绩预告未经注册会计师审计。 以上内容为证券 ...

最新公告列表 《迈得医疗工业设备股份有限公司2026年第一次临时股东会会议资料》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年1月29日收盘，迈得医疗（688310）报收于16.04元，较前一交易日下跌2.08%，最新总市值 为26.66亿元。该股当日开盘16.6元，最高16.89元，最低15.99元，成交额达9773.29万元，换手率为 3.59%。 近日，迈得医疗工业设备股份有限公司披露《2026年第一次临时股东会会议资料》，拟向控股子公司浙 江迈得顺隐形眼镜有限公司提供总额不超过人民币1亿元的财务资助，资助期限为自股东会审议通过之 日起3年内，借款利率参照一年期LPR，利息按实际借款占用天数计算。迈得顺可循环使用额度。公司 实际控制人林军华、持股5%以上股东陈万顺为本次资助提供连带责任保证。本次资助事项构成关联交 易，不构成重大资产重组。董事会已提请股东会授权管理层办理相关协议签署及款项支付等事宜。 ...

证券代码：688310 证券简称：迈得医疗 迈得医疗工业设备股份有限公司 2026 年第一次临时股东会会议资料 二〇二六年一月 1 | 2026 年第一次临时股东会会议须知 3 | | --- | | 2026 年第一次临时股东会会议议程 6 | | 2026 年第一次临时股东会会议议案 8 | | 议案一：关于向控股子公司提供财务资助暨关联交易的议案 8 | 迈得医疗工业设备股份有限公司 2026 年第一次临时股东会会议资料 迈得医疗工业设备股份有限公司 2026 年第一次临时股东会会议须知 为维护全体股东的合法权益，确保股东会会议秩序和议事效率，保证股东会 的顺利召开，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司股东会规则》以及《迈得医疗工业设备股份有限公司章程》《迈得医疗工业 设备股份有限公司股东会议事规则》等相关规定，特制定本会议须知： 一、公司负责本次股东会的议程安排和会务工作，为确认出席会议的股东或 其代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身份进行必 要的核对工作，请被核对者给予配合。 二、为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益，出席 会议 ...

Policy Developments - The National Health Commission released the "Guidelines for Clinical Application of New Antitumor Drugs (2025 Edition)" to standardize the clinical use of new antitumor drugs, which include small molecule targeted drugs and monoclonal antibodies [2] Drug and Device Approvals - North China Pharmaceutical announced it received a drug registration certificate for Tacrolimus capsules (0.5mg, 1mg), which is an immunosuppressant used to prevent organ transplant rejection [4] - A new lung cancer early diagnosis kit developed by the Hangzhou Institute of Medicine has been approved for market release, potentially improving early diagnosis rates for lung cancer [5] Financial Reports - YaoXingTang projected a net profit of 260 million to 330 million yuan for 2025, representing a year-on-year increase of 127.79% to 189.12%, driven by improved operational efficiency and resource allocation [7] - MaiDe Medical expects a revenue of approximately 447 million yuan for 2025, marking a year-on-year increase of about 62.81%, and anticipates a net profit of around 66.52 million yuan, indicating a turnaround from previous losses [8] Capital Market Activities - Tongrentang Medical submitted an IPO application to the Hong Kong Stock Exchange, with CICC as the sponsor [10] - New Jingzhiyuan Biotech completed over 200 million yuan in Series B financing, led by Xingze Capital and a well-known industry fund [11] Industry Developments - Over 40% of county-level traditional Chinese medicine hospitals have initiated the establishment of county medical communities, with a total of 3,099 such communities formed across 2,199 counties and cities [13] - The National Health Commission reported that all tertiary public traditional Chinese medicine hospitals have achieved full coverage in pediatrics, enhancing health services for children and the elderly [14]

Core Viewpoint - The company, Maide Medical Industrial Equipment Co., Ltd., anticipates significant growth in revenue and profitability for the year 2025, marking a turnaround from previous losses [2][9]. Group 1: Performance Forecast - The company expects to achieve an operating revenue of approximately 447.50 million yuan for 2025, representing an increase of about 172.65 million yuan, or 62.81% year-on-year [2]. - The net profit attributable to the parent company is projected to be around 66.52 million yuan, indicating a turnaround from a loss in the previous year [2]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is estimated at approximately 54.64 million yuan [3]. Group 2: Previous Year Performance - In the previous year, the total profit was reported at -29.23 million yuan [5]. - The net profit attributable to the parent company was -19.98 million yuan [6]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was -26.28 million yuan [7]. - The basic earnings per share for the previous year were -0.12 yuan [8]. Group 3: Reasons for Performance Change - The anticipated revenue growth is attributed to the company's effective production planning and delivery, alongside a focus on technological innovation and process iteration [9]. - The blood purification and medical device combination equipment sectors are performing well, particularly due to strong demand for medical consumables in the end market [9]. - The company is concentrating on research and market development for new products in the medical device combination equipment sector, which is expected to drive significant revenue growth [9].

Core Viewpoint - The company, Maide Medical, has released its 2025 annual performance forecast, indicating significant revenue growth and a return to profitability, primarily driven by increased sales in smart medical equipment [1]. Group 1: Financial Performance - As of January 26, 2026, Maide Medical's stock closed at 16.26 yuan, down 1.57% from the previous trading day, with a total market capitalization of 2.703 billion yuan [1]. - The company expects to achieve approximately 447.50 million yuan in revenue for 2025, representing a year-on-year growth of 62.81% [1]. - The net profit attributable to the parent company is projected to be around 66.52 million yuan, marking a return to profitability [1]. - The net profit after deducting non-recurring gains and losses is estimated to be about 54.64 million yuan [1]. Group 2: Revenue Drivers - The significant growth in revenue is primarily attributed to a substantial increase in sales of smart medical equipment, particularly in the drug and device combination sector [1].

截至2026年1月26日收盘，迈得医疗(688310)报收于16.26元，下跌1.57%，换手率1.94%，成交量3.23万 手，成交额5225.49万元。 资金流向 迈得医疗工业设备股份有限公司2025年年度业绩预告 经财务部门初步测算，预计迈得医疗2025年年度实现营业收入44,749.77万元左右，同比增长62.81%； 归属于母公司所有者的净利润为6,652.13万元左右，实现扭亏为盈；扣除非经常性损益后的净利润为 5,463.95万元左右。业绩增长主要得益于营业收入大幅提升，尤其是药械组合类智能装备收入显著增 长。本期业绩预告未经注册会计师审计。 1月26日主力资金净流出115.69万元；游资资金净流出11.45万元；散户资金净流入127.14万元。 业绩披露要点 业绩预告 迈得医疗发布业绩预告，预计2025年全年营业收入4.47亿元。迈得医疗发布业绩预告，预计2025年全年 扣非后净利润盈利约5463.95万元。迈得医疗发布业绩预告，预计2025年全年归属净利润盈利约6652.13 万元。 公司公告汇总 当日关注点 交易信息汇总 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010 ...